Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

West Nile Fever

Interventions

BIOLOGICAL: ChimeriVax-WN02 Low Dose
BIOLOGICAL: ChimeriVax-WN02 Medium Dose
BIOLOGICAL: ChimeriVax-WN02 High Dose
BIOLOGICAL: 0.9% Saline solution
BIOLOGICAL: ChimeriVax-WN02 High Dose
BIOLOGICAL: 0.9 % NaCl solution

Sponsor

Sanofi Pasteur, a Sanofi Company